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The minimal inhibitory concentrations (MICs) of aztreonam and cefotaxime were
determined against 400 isolates from urological in-patients with complicated and/or
hospital acquired urinary tract infections (UTT). Against the Gram-negative rods the
activities of both antibiotics were comparable except for higher activity of aztreonam
against Pseudomonas aeruginosa. The pharmacokinetic study in nine elderly patients
showed a prolonged plasma half life of aztreonam (2-7 h) as compared to younger
volunteers (1-6-1-9 h).
In a prospective randomized study 39 urological patients with complicated and/or
hospital acquired UTI were treated with 1 g aztreonam or cefotaxime iv twice daily
for 4 to 15 days. Cure was obtained in 5 out of 18 patients in the aztreonam and 7 out
of 20 patients in the cefotaxime group. There were 3 superinfections, 7 relapses and 3
reinfections in the aztreonam group and 1 failure, 1 superinfection, 6 relapses and 5
reinfections in the cefotaxime group. There was no significant difference in ther-
apeutic efficacy between the two antibiotics. Both antibiotics were tolerated well and
seem to be equally effective in the treatment of complicated UTI caused by sensitive
organisms.
Introduction
Aztreonam is a new monocyclic /Mactam antibiotic (Sykes et al., 1981) with high activity
against aerobic Gram-negative bacteria. Previous studies have shown that aztreonam is
eliminated predominantly through the kidneys and that its serum half-life is about
1 -6-1 -9 h (Swabb et al., 1982, 1983 a, b, c, Wise et al., 1982). The present paper describes
the in-vitro activity of aztreonam compared with that of cefotaxime against bacterial
isolates from urological patients with complicated and/or hospital acquired urinary tract
infections (UTI), the pharmacokinetics of aztreonam and the therapeutic efficacy of
aztreonam compared with that of cefotaxime in the treatment of complicated and/or
hospital acquired UTI.
Materials and methods
Antibiotics and chemicals
The antibiotics were supplied as follows: aztreonam by Squibb-Heyden, Munich,
Germany, and cefotaxime by Hoechst AG, Frankfurt, Germany. Antibiotic medium 1
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and Mueller-Hinton broth were obtained from Difco Laboratories, Detroit, Michigan,
USA and Merck, Darmstadt, Germany. Nutrient broth and blood agar base no. 2 were
from Oxoid Deutschland GmbH, WeseL, Germany.
Inulin was obtained from Laevosan, Linz, Austria; Conray 70* (a mixture of ioth-
alamic acid, sodium salt and megluminate) and pure iothalamic acid were from
Byk-Gulden, Konstanz, Germany.
In-vitro study: clinical isolates
In-vitro minimal inhibitory concentrations (MICs) of aztreonam and cefotaxime were
determined against 400 strains isolated from the urine of urologjcal in-patients with
complicated and/or hospital acquired UTT (bacterial counts ;> 103 cfu/ml). Only patients
with monoinfections were included in the study.
Subjects
Group I. Nine elderly patients (8 male, 1 female) with a mean age of 72-6 years (range
64-82 years), a mean body weight of 65-3 kg (range 53-1—79-8 kg) and a mean height of
l-63m (range 1-54-1-69 m) were recruited for the pharmacokinetic study. The subjects
had serum creatinine levels < 15 g/1. Written informed consent was obtained.
Group II. The subjects of the clinical study were 39 urological patients (27 male, 12
female) between the ages of 18 and 83 years. They had complicated and or/hospital
acquired UTI and significant bacteriuria with urinary counts of ^ 10s cfu/ml. All
patients gave informed written consent.
Pharmacokinetic study
Aztreonam, 1 g, was administered intravenously over 3min in 100 ml of sterile
physiological saline containing 50g inulin and 20ml Conray 70*, corresponding to
13-2 g iothalamic acid. Blood samples were taken immediately before and 5, 10, 20, 30,
45, 60, 90 min and 2, 4, 6 and 8 h after the dose. Urine samples were collected before and
at the following intervals: 0 to 2; 2 to 4; 4 to 6; 6 to 8 and 8 to 12 h after the administration
of aztreonam. The urine volumes were measured and aliquots were taken for assay.
Clinical study
The subjects of the clinical study group were randomized and treated intravenously
either with aztreonam (AZ) or with cefotaxime (CTX), 1 g bd, over 4-15 days. The
patients had not received antimicrobial therapy within 4 weeks before the study. Bacter-
ial urine cultures were performed prior to the therapy, during therapy, one or two days
after treatment (post-treatment), and one to four weeks (one patient six weeks) later
(follow-up). In addition urinalysis, haematology (erythrocyte, leucocyte and platelet
counts) and chemistry profiles (creatinine, BUN, total bilirubin, alkaline phosphatase,
SGOT, SGPT) were followed in each patient pre- and post-treatment. The patients were
closely watched for local and systemic adverse reactions to the antibiotics. Bacterio-
logical cure implied eradication of the primary offending organism and the absence of
superinfection or reinfections with different species during the following therapy. The
pathogens, isolated by standard microbiological techniques, were checked for purity
on blood agar plates and their identities were confirmed by Gram's stain, colonial
morphology and by use of the API-20 systems (API bioMerieux GmbH, Niirtingen,
Germany).
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Determination of the minimal inhibitory concentration (MIC)
For the in-vitro study the activities of aztreonam and cefotaxime were determined by
the agar dilution technique using doubling dilutions of the antibiotics from 128 to
0-015 mg/1 in Mueller-Hinton agar (Merck) as the test medium. Inoculum size was
10*cfu using a multipoint inoculator (Dynatech). For the clinical study the activities
of aztreonam and cefotaxime were assayed by the broth dilution method in Mueller-
Hinton broth (Difco) as the test medium. The isolated clinical strains were grown over-
night in nutrient broth (Oxoid) to give a viable count of about 109 cfu/ml. The final
inoculum size was 5 x 10s cfu/ml. After 18 h of incubation at 37°C the minimal
inhibitory concentrations (MICs) were read by eye. The MIC was defined as the lowest
concentration of the antibiotic that prevented visible growth of the micro-organism.
Assay of aztreonam
Aztreonam concentrations in serum and urine samples were determined microbiologi-
cally by the agar plate diffusion technique. The agar medium was antibiotic medium 1
and the test organism was Escherichia coli 6311/65 (Hoescht AG). Serum urine stan-
dards ranging from 0-5 to 100mg/1 were prepared in human serum and in phosphate
buffered saline, respectively. Samples and standards were assayed in triplicate. After
incubation overnight at 37°C the inhibition zones were measured with an accuracy of
01 mm.
Assay ofinulin
Inulin in serum and urine was estimated chemically according to Heyrovsky's method
(Heyrovsky, 1956). The chemical estimation of inulin is based on the hydrolysis of inulin
to fructose, which is determined photometrically by the colour formed upon reaction
with indole-3-acetic acid in hydrochloric acid. The interference by glucose was found to
be negligible.
Assay of iothalamic acid
Iothalamic acid was determined by HPLC according to a published procedure (Kees,
Grobecker & Naber, 1984) with minor modifications. In brief, serum (400 nl) was
deproteinized with acetonitrile (400 ul). The latter was removed by extraction into
dichloro-methane (2 ml) and an aliquot of the aqueous phase containing the iothalamic
acid was injected into the chromatographic system. Urine was centrifuged and injected
directly after dilution (1:20) with water. The liquid chromatograph consisted of a pump
M 6000 A, an autoinjector WISP 710 B, a fixed wavelength detector M 440, operating at
254 nm, a data module M 730 and a system controller M 720, all from Waters, Ass.,
D-6236 Eschborn, Germany. For separation a HIBAR* column (ID 125x4 mm) was
used prefilled with LiChrosorb* RP 18 silica (particle size 5 urn) from Merck, D-6200
Darmstadt, Germany. The mobile phase was a mixture of 880 ml water, 120 ml acetoni-
trile, 1 -40 g sodium acetate trihydrate, and 450 mg tetrabutylammonium hydrogensul-
phate. The pH was adjusted to 4-8 with acetic acid. The flow rate was maintained at
lOml/min resulting in a back pressure of 110 bar and a retention time of 4-0 min for
iothalamic acid.
Pharmacokinetic analysis
The pharmacokinetic parameters were obtained from serum concentrations by use of an
open two compartment model and the following equation for fitting the experimental
data: concentration=y4.e-(rl+B.e~*1.
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Figure 1. Serum concentrations of aztreonam in nine elderly patients after intravenous administration of 1 g
aztreonam (mean ± ID.).
Results
In-vitro study
The MIC values of aztreonam and cefotaxime for the 400 isolates cultured from the
urine are shown in Table I. The MICs of aztreonam against all but nine of the 265
Gram-negative isolates were 8 mg/1 or lower. The MICs against all but two of the
134 Gram-positive isolates were 128 mg/1 or higher. Cefotaxime inhibited 90-2% of the
Gram-negative and 470% of the Gram-positive isolates at 8 mg/1 or lower.
Pharmacokinetic study
The serum concentrations after injection of 1 g of aztreonam are shown in Figure 1. The
mean ±S.D. (range) serum half-life amounted to 2-7±0-8h (1-8-4-3 h). The mean
±s.D. (range) urinary concentrations of aztreonam were: 0-2 h 1598 ±554 mg/1 (906-
2716mg/l), 2-4h 1195±598 (647±2293), 4-6h 964±564 (272-1799), 6-8h 443±198
(109)-795), and 8-12 h 244± 140 mg/1 (7-9-449 mg/1).
In Table II the calculated pharmacokinetic parameters of aztreonam, inulin and ioth-
alamic acid are listed. The mean serum half-life of aztreonam (2-7 h) and iothalamic acid
(2-7 h), as well as the volume of distribution (each 27-5% of body weight) were slightly
higher than the corresponding parameters of inulin which is a marker for the
extracellular space. On the other hand, total clearances were of the same order (around
90 ml/min). The mean urinary recovery (Figure 2) within 12 h was 70% for aztreonam
and nearly 90% for the other two compounds. The high standard deviation of the urin-
ary recovery of aztreonam is striking.
The mean ± SJX (range) urinary recovery of aztreonam with respect to inulin was
82 ± 36% (33-143%) whereas that of iothalamic acid was 103 ± 5% (96-111 %).
There was no statistically significant linear correlation between the serum clearances
of aztreonam and inulin, but there was between iothalamic acid and those of inulin
(r = 0-91;J»< 0-05).
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Figure 2. Urinary concentrations (mean±s.D.) and cumulative urinary excretion (% of dose injected) in
nine elderly patients after intravenous administration of 1 g aztreonam.
Clinical study
In the patients with UTIs the following causative organisms (AZ/CTX) were found: E.
coli (8/9), Proteus mirabilis (3/5), Pseudomonas aeruginosa (1/3), Klebsiella pneumoniae
(5/0), Pr. vulgaris (1/1), Providencia stuartii (0/1), Enterobacter sp. (1/1), Citrobacter
freundii (0/2). There were three mixed infections (1/2) with E. coli and enterococci or
two different Proteus spp. respectively.
The causative organisms were eradicated in all patients in the aztreonam group and in
19 of 20 patients in the cefotaxime group (Table III).
One to two days after treatment significant bacteriuria was still found in three out of
19 patients in the aztreonam and in two out of 20 in the cefotaxime group. Definite cure
(no significant bacteriuria in post treatment or follow up among specimens) was obtai-
ned in five out of 18 patients in the aztreonam and in seven out of 20 patients in the
cefotaxime group. There were three superinfections (different species present one to two
days after therapy), seven relapses (same species present again at follow up), three
reinfections (different species found at follow up) in the aztreonam group (one patient
was not assessable); and one failure (same species one to two days after therapy), one
superinfection, six relapses and five reinfections in the cefotaxime group. There was no
significant difference in therapeutic efficacy between the two antibiotics.
In a total of nine patients (aztreonam 5, cefotaxime 4) all with pyuria, enterococci
were cultured from the urine on at least two occasions after the antibacterial treatment.
Seven of these patients were treated because of urinary tract infections which occurred
postoperatively. One patient had stones in the bladder and one patient a renal tumour.
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This last patient was treated with aztreonam for four days because of an E. coli infection.
Since the patient remained febrile and superinfection with enterococci occurred, treat-
ment was successfully changed to bacampiciUin.
Both antibiotics were well tolerated so that it was not necessary to stop therapy
because of adverse reactions. There were no biochemical signs or symptoms of renal,
hepatic or haematological toxicity.
Discussion
The therapeutic spectrum of cefotaxime includes the majority of staphylococci but
not enterococci. All Gram-positive strains are resistant to aztreonam. The
Gram-negative strains cultured from the urine of 400 urological in-patients were com-
parably sensitive to aztreonam and cefotaxime. Aztreonam, however, showed a greater
activity against Pseudomonas species.
The pharmacokinetics of aztreonam exhibited a prolonged plasma half life (2-7 h) in
elderly patients as compared to healthy volunteers (1-6—1-9 h). In an earlier study of
cefotaxime pharmacokinetics in geriatric patients (Naber & Adam, 1980), a prolonged
half life of about two hours was also found. In both the studies plasma concentrations
showed a fairly wide range. In elderly patients with prolonged half lives of aztreonam
and cefoxatime, doses given twice daily should be sufficient for the treatment of UTI. The
total plasma clearances of aztreonam, inulin and iothalamic acid are very comparable,
indicating that the major route by far for the renal excretion of aztreonam is via glomer-
ular filtration. Since at low concentrations the chemical analysis of inulin is difficult,
plasma concentrations could only be measured up to 4-6 h after iv administration of 5 g.
Therefore in the study iothalamic acid was also administered. This compound, clinically
used as contrast medium for urography, is as suited as inulin for the determination of
glomerular filtration rate (Sigman, Elwood & Knox, 1965). After injection of 20 ml
Conray 70*, corresponding to 13-2 g iothalamic acid, plasma concentrations can easily be
measured by HPLC up to 24 h after injection. During and immediately after therapy
high success rates were achieved with both the antibiotics. However, definite cure (no
bacteriuria found within follow up period), could only be observed in about one-third of
the patients regardless of the antibiotic used. Comparable results were obtained in two
other studies of urological patients treated with different antimicrobial compounds
(Naber & Bauernfeind, 1982; Naber & Wittenberger, 1985). Relapses and reinfections
are common phenomena following the treatment of complicated UTI. In these cases
underlying anatomical or functional abnormalities may serve as a nidus of infection and
prevent complete eradication of bacteria.
The high rate of reinfections with enterococi (nine cases) occurred predominantly in
postoperative patients. This may have been due to the epithelial lesions present within
the urinary tract and the resistance of this species against both of these antibiotics.
Aztreonam and cefotaxime were tolerated well without any side effects. Both the
antibiotics seem to be equally suited for the treatment of complicated UTIs caused
by sensitive organisms. However, one should be aware of possible reinfections with
enterococci.
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